



60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

December 11, 2025 1:01 PM EST

- 6-month commercial pilot demonstrated increasing demand among prescribers
- Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign
- Additional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company's breakthrough therapy designation request

WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- [60 Degrees Pharmaceuticals, Inc.](#) (NASDAQ: SXTX; SXTXW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the planned expansion of the Company's sales and marketing initiatives after encouraging results from a 6-month commercial pilot that showed an overall increase in product sales. The positive outcome points to increasing market demand for ARAKODA® among prescribers.

In response to the encouraging results, the Company will implement several strategic initiatives designed to expand market reach and accelerate ARAKODA sales in 2026:

- **Inside Sales Team Expansion:**
The number of inside sales representatives will increase to deepen outreach across prescribers, strengthen provider relationships, and enhance product education and support.
- **GoodRx Partnership for Broader Offer Visibility:**
The Company will engage with GoodRx to provide wider coverage of its point-of-sale (POS) ARAKODA offer, enabling patients and prescribers to access savings information more efficiently.
- **Enhanced Digital "Surround Sound" Campaign:**

Building on initial successes, the ARAKODA Marketing team will continue to optimize its integrated digital marketing campaign, ensuring high-frequency awareness, relevant targeting, and sustained engagement across prescriber audiences.

"Results of our commercial pilot intended to measure market demand among prescribers demonstrated increasing demand trends," said Chief Executive Officer, Geoff Dow, PhD. "The investments we plan for 2026 reflect our commitment to expand reach, improve access, and support healthcare providers and patients with what we consider to be best-in-class malaria prevention."

In addition, the Company will add at least two babesiosis clinical sites for its randomized placebo-controlled study in hospitalized babesiosis patients ([NCT06207370](#)) and its expanded access study in high risk patients with treatment refractory relapsing disease ([NCT06478641](#)), in response to U.S. Food and Drug Administration (FDA) feedback in a recent communication regarding the Company's request for Breakthrough Therapy Designation. In declining that request, FDA acknowledged that babesiosis meets the criteria for being classified as a serious or life-threatening disease or condition, one of the requirements for being considered for a Breakthrough Therapy Designation, and suggested that the Company resubmit its request with data from ongoing controlled clinical trials for babesiosis treatment.

The new clinical sites may increase the likelihood of enrolling such patients on a more condensed timeline.

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA. The safety of the approved regimen of **tafenoquine** for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for duration of up to six months. **Tafenoquine** has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such an indication.

About ARAKODA® (tafenoquine)

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of **tafenoquine** for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months.

Tafenoquine was discovered by Walter Reed Army Institute of Research, and the current study was funded by the United States Army Medical & Materiel Development Activity. **Tafenoquine** was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug.

According to the Centers for Disease Control and Prevention, the long terminal half-life of **tafenoquine**, which is approximately 16 days, may offer

potential advantages in less-frequent dosing for prophylaxis for malaria. ARAKODA[®] is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA[®] 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.

ARAKODA[®] (tafenoquine) Important Safety Information

ARAKODA[®] is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.

Contraindications

ARAKODA[®] should not be administered to:

- Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency or unknown G6PD status;
- Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if
- G6PD status is unknown;
- Patients with a history of psychotic disorders or current psychotic symptoms; or
- Known hypersensitivity reactions to **tafenoquine**, other 8-aminoquinolines, or any component of ARAKODA[®].

Warnings and Precautions

Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA[®] due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.

G6PD Deficiency in Pregnancy or Lactation: ARAKODA[®] may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA[®] is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA[®] through breast milk. Check infant’s G6PD status before breastfeeding begins.

Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.

Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA[®] therapy and evaluation by a mental health professional as soon as possible.

Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA[®]. If hypersensitivity reactions occur, institute appropriate therapy.

Delayed Adverse Reactions: Due to the long half-life of ARAKODA[®] (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.

Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety.

Drug Interactions

Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters.

Use in Specific Populations

Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA[®]. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA[®] is located [here](#).

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA[®] (**tafenoquine**), for malaria prevention, in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our

management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for **tafenoquine** (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:

Sheila A. Burke

SheilaBurke-consultant@60degreespharma.com

(484) 667-6330

Investor Contact:

Patrick Gaynes

patrickgaynes@60degreespharma.com



Source: Sixty Degrees Pharmaceuticals